<?xml version='1.0' encoding='utf-8'?>
<document id="24825411"><sentence text="Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers."><entity charOffset="33-42" id="DDI-PubMed.24825411.s1.e0" text="darunavir" /><entity charOffset="43-52" id="DDI-PubMed.24825411.s1.e1" text="ritonavir" /><entity charOffset="57-69" id="DDI-PubMed.24825411.s1.e2" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.24825411.s1.e0" e2="DDI-PubMed.24825411.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24825411.s1.e0" e2="DDI-PubMed.24825411.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s1.e0" e2="DDI-PubMed.24825411.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24825411.s1.e1" e2="DDI-PubMed.24825411.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s1.e1" e2="DDI-PubMed.24825411.s1.e2" /></sentence><sentence text="The treatment of hyperlipidaemia in human immunodeficiency virus (HIV)-infected patients has become increasingly important" /><sentence text=" However, treatment options are limited because of the drug-drug interaction between certain statins and HIV medications metabolized by cytochrome P450 (CYP) enzymes" /><sentence text="" /><sentence text="The primary objective was to investigate the steady-state pharmacokinetics of pitavastatin when co-administered with darunavir/ritonavir"><entity charOffset="78-90" id="DDI-PubMed.24825411.s5.e0" text="pitavastatin" /><entity charOffset="117-126" id="DDI-PubMed.24825411.s5.e1" text="darunavir" /><entity charOffset="127-136" id="DDI-PubMed.24825411.s5.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.24825411.s5.e0" e2="DDI-PubMed.24825411.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24825411.s5.e0" e2="DDI-PubMed.24825411.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s5.e0" e2="DDI-PubMed.24825411.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24825411.s5.e1" e2="DDI-PubMed.24825411.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s5.e1" e2="DDI-PubMed.24825411.s5.e2" /></sentence><sentence text=" The secondary objective was to investigate the steady-state pharmacokinetics of both darunavir and ritonavir when co-administered with pitavastatin"><entity charOffset="86-95" id="DDI-PubMed.24825411.s6.e0" text="darunavir" /><entity charOffset="100-109" id="DDI-PubMed.24825411.s6.e1" text="ritonavir" /><entity charOffset="136-148" id="DDI-PubMed.24825411.s6.e2" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.24825411.s6.e0" e2="DDI-PubMed.24825411.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24825411.s6.e0" e2="DDI-PubMed.24825411.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s6.e0" e2="DDI-PubMed.24825411.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24825411.s6.e1" e2="DDI-PubMed.24825411.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s6.e1" e2="DDI-PubMed.24825411.s6.e2" /></sentence><sentence text="" /><sentence text="This was a single-centre, open-label, multi-dose, fixed-sequence study in HIV seronegative healthy volunteers" /><sentence text=" Pitavastatin 4 mg was administered once daily on days 1-5 and on days 12-16, and darunavir 800 mg/ritonavir 100 mg once daily on days 6-16"><entity charOffset="1-13" id="DDI-PubMed.24825411.s9.e0" text="Pitavastatin" /><entity charOffset="82-91" id="DDI-PubMed.24825411.s9.e1" text="darunavir" /><entity charOffset="99-108" id="DDI-PubMed.24825411.s9.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.24825411.s9.e0" e2="DDI-PubMed.24825411.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24825411.s9.e0" e2="DDI-PubMed.24825411.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s9.e0" e2="DDI-PubMed.24825411.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24825411.s9.e1" e2="DDI-PubMed.24825411.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s9.e1" e2="DDI-PubMed.24825411.s9.e2" /></sentence><sentence text=" Pharmacokinetic blood sampling was performed on days 5, 11 and 16" /><sentence text=" No significant interaction was concluded if the 90 % confidence intervals (CIs) of the geometric mean ratios (GMRs) for total exposure [i" /><sentence text="e" /><sentence text=" the area under the plasma concentration-time curve over a dosing interval at steady state (AUC(0-τ))] and for peak exposure [i" /><sentence text="e" /><sentence text=" the maximum plasma concentration (C(max))] of the two treatments were within the 80-125 % range" /><sentence text="" /><sentence text="Twenty-eight subjects (mean age 30" /><sentence text="5 years) were enrolled, and pharmacokinetic data were available for 27 subjects" /><sentence text=" For pitavastatin, the GMRs and 90 % CIs for the AUC(0-τ) and C(max) ratios with co-administration were 0"><entity charOffset="5-17" id="DDI-PubMed.24825411.s19.e0" text="pitavastatin" /><entity charOffset="49-57" id="DDI-PubMed.24825411.s19.e1" text="AUC(0-τ)" /><pair ddi="false" e1="DDI-PubMed.24825411.s19.e0" e2="DDI-PubMed.24825411.s19.e0" /><pair ddi="false" e1="DDI-PubMed.24825411.s19.e0" e2="DDI-PubMed.24825411.s19.e1" /></sentence><sentence text="74 (0" /><sentence text="69-0" /><sentence text="80) and 0" /><sentence text="96 (0" /><sentence text="84-1" /><sentence text="09), respectively" /><sentence text=" For both darunavir and ritonavir, the 90 % CIs for the AUC(0-τ) and C max ratios were within 80-125 % with pitavastatin co-administration"><entity charOffset="10-19" id="DDI-PubMed.24825411.s26.e0" text="darunavir" /><entity charOffset="24-33" id="DDI-PubMed.24825411.s26.e1" text="ritonavir" /><entity charOffset="56-64" id="DDI-PubMed.24825411.s26.e2" text="AUC(0-τ)" /><entity charOffset="108-120" id="DDI-PubMed.24825411.s26.e3" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.24825411.s26.e0" e2="DDI-PubMed.24825411.s26.e0" /><pair ddi="false" e1="DDI-PubMed.24825411.s26.e0" e2="DDI-PubMed.24825411.s26.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s26.e0" e2="DDI-PubMed.24825411.s26.e2" /><pair ddi="false" e1="DDI-PubMed.24825411.s26.e0" e2="DDI-PubMed.24825411.s26.e3" /><pair ddi="false" e1="DDI-PubMed.24825411.s26.e1" e2="DDI-PubMed.24825411.s26.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s26.e1" e2="DDI-PubMed.24825411.s26.e2" /><pair ddi="false" e1="DDI-PubMed.24825411.s26.e1" e2="DDI-PubMed.24825411.s26.e3" /><pair ddi="false" e1="DDI-PubMed.24825411.s26.e2" e2="DDI-PubMed.24825411.s26.e2" /><pair ddi="false" e1="DDI-PubMed.24825411.s26.e2" e2="DDI-PubMed.24825411.s26.e3" /></sentence><sentence text=" No significant safety issues were reported" /><sentence text="" /><sentence text="Darunavir/ritonavir decreased total exposure to pitavastatin by 26 %, while peak exposures were similar"><entity charOffset="0-9" id="DDI-PubMed.24825411.s29.e0" text="Darunavir" /><entity charOffset="10-19" id="DDI-PubMed.24825411.s29.e1" text="ritonavir" /><entity charOffset="48-60" id="DDI-PubMed.24825411.s29.e2" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.24825411.s29.e0" e2="DDI-PubMed.24825411.s29.e0" /><pair ddi="false" e1="DDI-PubMed.24825411.s29.e0" e2="DDI-PubMed.24825411.s29.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s29.e0" e2="DDI-PubMed.24825411.s29.e2" /><pair ddi="false" e1="DDI-PubMed.24825411.s29.e1" e2="DDI-PubMed.24825411.s29.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s29.e1" e2="DDI-PubMed.24825411.s29.e2" /></sentence><sentence text=" Pitavastatin did not influence the pharmacokinetics of darunavir or ritonavir"><entity charOffset="1-13" id="DDI-PubMed.24825411.s30.e0" text="Pitavastatin" /><entity charOffset="56-65" id="DDI-PubMed.24825411.s30.e1" text="darunavir" /><entity charOffset="69-78" id="DDI-PubMed.24825411.s30.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.24825411.s30.e0" e2="DDI-PubMed.24825411.s30.e0" /><pair ddi="false" e1="DDI-PubMed.24825411.s30.e0" e2="DDI-PubMed.24825411.s30.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s30.e0" e2="DDI-PubMed.24825411.s30.e2" /><pair ddi="false" e1="DDI-PubMed.24825411.s30.e1" e2="DDI-PubMed.24825411.s30.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s30.e1" e2="DDI-PubMed.24825411.s30.e2" /></sentence><sentence text=" There is limited interaction between pitavastatin and darunavir/ritonavir"><entity charOffset="38-50" id="DDI-PubMed.24825411.s31.e0" text="pitavastatin" /><entity charOffset="55-64" id="DDI-PubMed.24825411.s31.e1" text="darunavir" /><entity charOffset="65-74" id="DDI-PubMed.24825411.s31.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.24825411.s31.e0" e2="DDI-PubMed.24825411.s31.e0" /><pair ddi="false" e1="DDI-PubMed.24825411.s31.e0" e2="DDI-PubMed.24825411.s31.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s31.e0" e2="DDI-PubMed.24825411.s31.e2" /><pair ddi="false" e1="DDI-PubMed.24825411.s31.e1" e2="DDI-PubMed.24825411.s31.e1" /><pair ddi="false" e1="DDI-PubMed.24825411.s31.e1" e2="DDI-PubMed.24825411.s31.e2" /></sentence><sentence text="" /></document>